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Context: Aromatase deficiency causes obesity and insulin resistance in aromatase knockout mice
and humans with rare mutations of the aromatase gene (CYP19). Aromatase inhibitors are a
commonly prescribed therapy for postmenopausal breast cancer.
Objective: We hypothesized that aromatase inhibitors induce obesity and insulin resistance when
used in treatment of breast cancer.
Design: Case-control study.
Setting: University teaching hospital.
Participants: Patientswith postmenopausal breast cancer (n5 20) treatedwith aromatase inhibitors
and 20 age-matched control subjects.
Main outcome measures: The primary outcome measure was insulin sensitivity index – Matsuda,
derived from a 75-g oral glucose tolerance test. Body composition was assessed by dual energy x-ray
absorptiometry and biopsy specimens of subcutaneous adipose tissue obtained for assessment of
mRNA transcript levels. Data are reported as mean 6 SEM (patients receiving inhibitors vs control
group, respectively).
Results: Aromatase inhibitor therapy was associated with significantly lower insulin sensitivity
(5.156 0.45 vs 6.806 0.64; P5 0.041), higher peak insulin concentration after oral glucose tolerance
test (693.46 78.6 vs 527.66 85.5 pmol/L; P5 0.035), greater percentage of body fat (38.4%6 1.0%
vs 34.6%6 1.3%; P5 0.026), and higher plasma leptin concentration (23.56 2.8 vs 15.56 2.3 ng/mL;
P 5 0.035).
Conclusion: Women who received aromatase inhibitors for postmenopausal breast cancer had
greater percentage body fat and insulin resistance compared with control subjects with no history
of breast cancer. (J Clin Endocrinol Metab 104: 3670–3678, 2019)
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Manipulation of estrogen receptor (ER) signaling hasbeen a central component in the management of
hormone-receptor–positive breast carcinoma in post-
menopausal women for over two decades. More than 1.5
million prescriptions are issued annually for hormonal
breast cancer therapies in England (1). Tamoxifen (an ER
partial agonist) and third-generation aromatase inhibitors
(e.g., anastrozole, letrozole, exemestane) are associated
with increased disease-free survival. However, aromatase
inhibitor therapy has been associated with an increased
risk of cardiovascular disease (2), when compared with
tamoxifen therapy. The effects of aromatase inhibition
on lipid profile have been widely investigated (3), with
mixed results, and do not necessarily represent a class
effect.
After menopause, the previously lower risk of car-
diovascular disease in women increases to converge with
that of men (4). Type 2 diabetes appears to develop in
men at a lower body mass index (BMI) than women (5),
potentially as a consequence of estrogen-related differ-
ences in body fat distribution (6). Hormone replacement
therapy reduces the risk of diabetes, with a number
needed to treat of 30 to prevent one case (7). Post-
menopausal plasma estradiol levels are $50% lower
than those observed in men. It follows that aromatase
inhibition, by further lowering circulating estradiol levels,
may result in an exaggerated postmenopausal phenotype.
This may be particularly pronounced in adipose tissue,
because aromatase inhibitors have an even greater sup-
pressive effect on estradiol in breast tumor tissue than on
circulating estradiol concentration in women with breast
cancer (8).
Aromatase knockout mice (9, 10) and rare human
examples of congenital aromatase deficiency (11) are
associated with increased adiposity, hepatic steatosis,
and insulin resistance. We have previously reported in-
creased insulin resistance in healthy men after 6 weeks’
treatment with an aromatase inhibitor (12). However,
the effects of aromatase inhibition on insulin sensitivity
have not been assessed in postmenopausal women, the
group most likely to be exposed to aromatase inhibitor
therapy. We sought to investigate this potential associ-
ation by performing a case-control study comparing
postmenopausal women with breast cancer treated
with an aromatase inhibitor with age-matched healthy
volunteers.
Methods
Study design
This was a case-control study, comparing women with
breast cancer who were receiving aromatase inhibitor ther-
apy, with age-matched healthy control subjects. Twenty
postmenopausal women were recruited from the Edinburgh
Breast Cancer Clinic. The inclusion criteria were a diagnosis of
ER-positive breast carcinoma and current aromatase inhibitor
therapy (either anastrozole, letrozole, or exemestane) for at
least 1 year. Twenty age-matched postmenopausal control
subjects without breast cancer or aromatase inhibitor ther-
apy were recruited from the South East Scotland Breast
Cancer Screening service. All participants were white Eu-
ropean. Exclusion criteria for both groups were metastatic
breast carcinoma, important medical comorbidities, hormone
replacement therapy, previous diagnosis of diabetes mellitus
and recent (i.e., within 3 months) therapy with glucocorticoids.
Ethical approval was granted from the Lothian Research Ethics
Committee and all participants provided written informed
consent.
Study protocol
Subjects attended the clinical research facility at 8:30 AM
after an overnight fast and were asked to abstain from alcohol,
tobacco, and caffeine starting the evening before attendance.
An oral glucose tolerance test (sampling at 230, 215,
0, 130, 160, 190, and 1120 minutes, in reference to 75 g of
anhydrous glucose) and basic anthropometric measurements
(i.e., weight, height, waist and hip circumferences) were taken.
Systolic and diastolic blood pressures and pulse rate were
measured after sitting for $10 minutes, using a 705IT au-
tomatic blood pressure monitor (OMRON Health care,
Hoofddorp, Netherlands). At completion of the oral glucose
tolerance test, a subcutaneous adipose needle biopsy was
performed (13). On a separate day, within 2 months of the
first visit, subjects attended the Western General Hospital
for a dual energy x-ray absorptiometry scan (Discovery A,
Hologic, Bedford MA). Estimated bone mineral content, fat
mass, lean mass, and percentage fat were reported for five
separate compartments: head, trunk, left arm, right arm, left
leg, and right leg. The proportion of android fat was calcu-
lated as follows: (trunk fat 1 arm fat)/total body fat. The
proportion of gynoid fat was calculated as follows: leg fat/
total body fat (14). The fat distribution index was the ratio of
trunk to leg fat (15). The Scottish Index of Multiple Depri-
vation score was used to assess the deprivation status of
participants (based on 38 measures across 7 categories in
6505 geographical “data zones”) (16).
Laboratory assays
Fasting lipid profile (including total cholesterol, triglyceride,
low-density lipoprotein cholesterol and high-density lipopro-
tein cholesterol levels) and glucose levels were analyzed on the
Vitros platform (Ortho-Clinical Diagnostics, High Wycombe,
UK); insulin was analyzed using a chemiluminescent micro-
particle immunoassay (Architect 8K41, Abbott Laboratories,
Wiesbaden, Germany) and adiponectin, resistin, leptin, MCP-1,
and IL-8 were analyzed by multiplex immunoassay (Merck
Millipore, Watford, UK). Plasma testosterone, androstene-
dione, estradiol, and estrone levels were quantified by liquid
chromatography–tandem mass spectrometry, as described
previously (13, 17). SHBG was analyzed by immunoassay
on the Roche E411 analyzer (Roche Diagnostics, Burgess
Hill, UK).
Adipose tissue was processed, RNA extracted, and after
reverse transcription, quantitative PCR was performed to an-
alyze the mRNA transcript levels of a panel of genes related to
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adipogenesis, steroid metabolism, and adipocytokines, nor-
malized against the abundance of cyclophilin (12). Cyclophilin
expression was not different between patients and control
subjects (P 5 0.35).
Data analysis and statistical methods
Insulin sensitivity index – Matsuda (hereafter, Matsuda
index) was calculated as previously described (18). All statistical
analyses were carried out using SPSS Statistics for Windows,
version 19.0, software (IBM, Armonk, NY). Data are presented
as mean 6 SEM (patient group vs control group, respectively)
unless otherwise stated.
Comparisons between patients and control subjects were
performed using independent-samples Student t tests when data
were normally distributed. When data were not normally
distributed, as determined by the Kolmogorov-Smirnov test,
logarithmic transformation was performed and subsequently
compared with Student t tests if a normal distribution was
obtained or by independent-samples Mann-Whitney U tests if
transformed data remained not normally distributed. Assess-
ment of the influence of covariates was performed using
analysis of covariance. Correlation between normally distrib-
uted variables was performed using the Pearson correlation
coefficient, and the influence of potential confounders was
assessed bymultiple linear regression. Participant numbers were
chosen to provide 80% power to detect a 50% difference in
insulin sensitivity index (19). Statistical significance was ac-
cepted at P , 0.05.
Results
Subject characteristics
Anastrozole was the aromatase inhibitor used most
prevalently (n 5 12), with the remaining participants
receiving letrozole (n 5 6) and exemestane (n 5 2). The
mean duration of aromatase inhibitor therapy was
27.4 6 2.8 months. Patients and control subjects were
well matched with respect to age [61.4 6 1.4 (range, 51
to 72) vs 59.4 6 1.0 (range, 52 to 67) years; P 5 0.259],
BMI (27.1 6 0.8 vs 26.6 6 1.0 kg/m2; P 5 0.68), and
Scottish Index of Multiple Deprivation scores (4806 6
355 vs 5013 6 419; P 5 0.71). Of the 20 patients, five
had previously received systemic chemotherapy, al-
though this was not associated with important dif-
ferences in any of the parameters measured. Regular
medication use was largely limited to levothyroxine re-
placement (seven patients, one control subject) and an-
tihypertensive agents (four patients, one control subject).
Four patients were receiving bendroflumethiazide, but
this was not associated with any difference in indices of
insulin sensitivity. There was no difference in fasting lipid
profile (Table 1) or systolic blood pressure between
patients and control subjects (139 6 4 vs 131 6 3 mm
Hg; P5 0.140) but diastolic blood pressure was higher in
patients receiving aromatase inhibitor treatment (82 6 2
vs 75 6 2 mm Hg; P , 0.05).
Sex steroid hormones
Plasma estradiol and estrone concentrations were,
respectively, 47% (P , 0.001) and 40% (P , 0.001)
lower in patients treated with aromatase inhibitors than
in control subjects (Table 1). Testosterone concentration
and free androgen index were not significantly different
between groups, although androstenedione concentration
Table 1. Fasting Lipid Profile, and Sex Steroid and Adipokine Levels
Patients (n 5 20) Control Subjects (n 5 20) Pa
Total cholesterol, mmol/L 6.0 (0.1) 5.7 (0.2) NS
HDL cholesterol, mmol/L 1.6 (0.1) 1.7 (0.1) NS
LDL cholesterol, mmol/L 3.8 (0.1) 3.5 (0.2) NS
Triglycerides, mmol/L 1.1 (0.1) 1.0 (0.1) NS
Cholesterol to HDL-C ratio 3.8 (0.2) 3.5 (0.2) NS
Estradiol, pmol/L 18.7 (0.8) 35.5 (1.2) ,0.001
Estrone, pmol/L 16.2 (0.7) 26.9 (1.1) ,0.001
Testosterone, nmol/L 0.66 (0.03) 0.70 (0.02) NS
Androstenedione, nmol/L 0.47 (0.02) 0.54 (0.03) 0.04
Free androgen index 1.06 (0.14) 0.91(0.11) NS
SHBG, nmol/L 82 (8) 77 (9) NS
Testosterone to estradiol ratio 38.6 (2.1) 19.4 (1.5) ,0.001
Androstenedione to estrone ratio 34.8 (2.2) 18.3 (1.2) ,0.001
Leptin, ng/mL 23.5 (2.8) 15.5 (2.3) 0.035b
Adiponectin, mg/mL 43.0 (5.9) 35.4 (3.7) NS
IL-8, pg/mL 7.6 (1.1) 6.7 (0.6) NS
MCP-1, pg/mL 292.5 (33.8) 268.3 (20.2) NS
Resistin, pg/mL 22.2 (1.1) 22.9 (1.9) NS
Data are reported as mean (SEM).
Abbreviations: HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; NS, not significant.
aData were compared by Student t tests or independent-samples Mann-Whitney U test (where data were not normally distributed even after log
transformation).
bMann-Whitney U test.
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was 13% lower (P 5 0.04) in patients treated with
aromatase inhibitors (Table 1). Estradiol concentration
was significantly negatively correlated with insulin sen-
sitivity index in patients (R520.497; P5 0.03) but not
control subjects (R 5 20.006; P 5 0.982) (20). The
association between estradiol and insulin sensitivity in-
dex was no longer significant after adjustment for per-
centage body fat in a multiple regression model (20). No
other significant correlations were observed between sex
steroid hormones and either insulin sensitivity or per-
centage body fat (Table 2).
Body composition
Although there were no significant differences in an-
thropometric measures of body composition (Table 3),
dual-energy x-ray absorptiometry revealed lower lean
mass in patients than in control subjects across almost all
compartments (Table 3). Total fat mass and trunk fat
were not different, but peripheral percentage body fat
was greater in patients receiving aromatase inhibitor
treatments than in control subjects (Table 3). Fat dis-
tribution index (i.e., the ratio of trunk to leg fat) did not
differ between groups.
Insulin sensitivity
All 40 participants had normal fasting blood glucose
levels (i.e., ,6 mmol/L), with six participants in the
aromatase inhibitor group having impaired glucose tol-
erance (glucose level, 7.8 to 11.0 mmol/L at 2 hours after
ingesting 75 g of oral glucose) compared with three
participants in the control group. In addition, two par-
ticipants in the control group had 2-hour glucose levels in
the diagnostic range for diabetes (i.e., .11 mmol/L).
Three patients and two control subjects fulfilled the In-
ternational Diabetes Federation criteria for metabolic
syndrome. Patients receiving aromatase inhibitor treat-
ment were significantly more insulin resistant than
control subjects, with a 24% lower Matsuda index
(5.15 6 0.45 vs 6.80 6 0.64; P 5 0.041), an effect in-
dependent of age but not body fat percentage. Peak in-
sulin concentration was also greater in patients than in
control subjects (693.4 6 78.6 vs 527.6 6 85.5 pmol/L;
P 5 0.035; Fig. 1). Homeostatic model assessment of
insulin resistance (HOMA-IR) did not differ between
patients and control subjects (1.41 6 0.16 vs 1.23 6
0.16; P 5 0.365).
Adipokines and proinflammatory cytokines
Serum leptin levels were higher in patients receiving
aromatase inhibitors (Table 1), although this relationship
did not persist when adjusted for percentage body fat. IL-
8, MCP-1, adiponectin, and resistin values did not differ
between patients and control subjects (Table 1). Ta
b
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Subcutaneous adipose tissue mRNA
In subcutaneous adipose tissue, increased abundance
of mRNA of genes encoding LKB1 (32%; P 5 0.03),
b-catenin (27%; P 5 0.023), and leptin (40%; P 5
0.003) was observed in patients. There were non-
significant trends toward greater expression of perilipin 2
(21%; P 5 0.077), PPARg (25%; P 5 0.087), and li-
poprotein lipase (14%; P 5 0.086) in patients compared
with control subjects. The full results for all genes
assessed are presented in Table 4.
Discussion
These data show that women with breast cancer treated
with aromatase inhibitors are more insulin resistant and
have greater percentage body fat than healthy control
subjects. The primary outcome measure was the Matsuda
index,whichwas selected because it integrates information
from the glucose and insulin values in the fasting and fed
states to provide an estimate of insulin sensitivity that
accords well with gold standard glucose clamp studies
(18). We previously demonstrated decreased peripheral
glucose disposal in healthy men treated with anastrozole
(12), and the hyperinsulinemia after a glucose load dem-
onstrated in the current study is consistent with a similar
effect in postmenopausal women. We have not tested the
underlying mechanism but suspect it relates to estrogen
deficiency following aromatase inhibition, particularly
because circulating estrogens were lower in women treated
with an aromatase inhibitor, but androgens were not el-
evated. Our hypothesis is supported by emerging obser-
vational data suggesting a greater than fourfold increased
risk of incident diabetes associated with aromatase in-
hibitor therapy in postmenopausal women with breast
cancer (21). In the patients treated with aromatase in-
hibitors (but not control subjects), plasma estradiol level
was negatively associated with insulin sensitivity. This was
not independent of percentage body fat and is consistent
with previous observations that aromatase inhibitor
suppression of plasma estradiol is attenuated in obesity
(22). Indeed, target-tissue estrogen levels correlate poorly
with plasma levels (23), and most estrogen action in
postmenopausal women is likely to be mediated by local
generation at target tissues (e.g. 20-fold higher estradiol in
fat than plasma) (24).
Table 3. Anthropometric Measurements and detailed Dual Energy X-Ray Absorptiometry Body Composition
Analysis
Patients (n 5 20) Control Subjects (n 5 20) Pa
Height, cm 159.8 (0.9) 165.1 (1.7) 0.001
Weight, kg 69.2 (2.3) 72.5 (2.9) NS
BMI, kg/m2 27.1 (0.9) 26.6 (1.0) NS
Waist circumference, cm 90.1 (2.0) 88.4 (2.6) NS
Hip circumference, cm 102.3 (1.6) 103.4 (1.8) NS
Waist to hip ratio 0.88 (0.01) 0.85 (0.01) NS
Total bone mineral content, kg 1.92 (0.06) 2.05 (0.08) NS
Total body fat, kg 26.72 (1.49) 25.61 (2.01) NS
Total body lean mass, kg 40.28 (9.29) 44.72 (14.94) 0.014
Total body fat, % 38.4 (1.0) 34.6 (1.3) 0.026
Fat distribution index 1.3 (0.1) 1.3 (0.1) NS
Proportion android fat 0.6 (0.01) 0.6 (0.02) NS
Proportion gynoid fat 0.4 (0.01) 0.4 (0.01) NS
Data presented as mean (SEM).
Abbreviation: NS, not significant.
aCompared by Student t test.
Figure 1. Graphs showing changes in (A) plasma insulin and (B)
glucose levels across 2-hour 75-g oral glucose tolerance test. Data
are reported as mean 6 SEM.
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Estrogen deficiency at menopausal transition is as-
sociated with increased visceral adiposity and its atten-
dant associations with cardiometabolic risk factors (25).
Conceivably, by additional profound suppression of
estrogen, aromatase inhibition has the potential to ex-
acerbate this phenotype. Only two previous studies have
assessed the effect of aromatase inhibition on body
composition and both were potentially confounded by
participants in the comparator groups receiving ta-
moxifen, which may increase visceral adiposity (26). In
one study, 11 recently menopausal participants with
breast cancer who were receiving aromatase inhibitors
were compared with 71 women receiving alternative
therapies (mostly tamoxifen). Over 24 months, those
treated with aromatase inhibitors gained lean mass,
whereas those not receiving aromatase inhibitors had
increased body fat (27). Our findings of reduced lean
mass and greater percentage body fat with correspond-
ingly elevated serum leptin are not entirely congruent
with these earlier investigations, but our comparator
group did not receive tamoxifen. However, our findings
of lower lean mass, higher serum leptin levels, and higher
adipose tissue mRNA for lipoprotein lipase and leptin
are consistent with estrogen deficiency and opposite to
known estrogen effects on fat and muscle (28–30).
Moreover, similar elevations in adipose leptin mRNA
levels were observed in aromatase knockout mice, and
the levels were lowered by estradiol administration (31).
We assessed a range of mRNA transcript levels in
subcutaneous adipose tissue, on the basis of previous
Table 4. Subcutaneous Adipose TissuemRNA Transcript Levels in Patients TreatedWith Aromatase Inhibitors
and in Control Subjects
Patients (n 5 20) Control Subjects (n 5 18) P
Steroid hormone synthesis and metabolism
HSD11B1, 11bHSD1 0.91 6 0.15 0.78 6 0.10 NSa
AKR1C2, aldo-keto reductase 1C2 1.01 6 0.20 0.80 6 0.11 NSa
CYP19A1 aromatase 0.66 6 0.14 0.42 6 0.09 NSa
Steroid hormone receptors
AR, androgen receptor 0.77 6 0.06 0.71 6 0.05 NSa
ESR1, estrogen receptor a 0.74 6 0.10 0.59 6 0.07 NSa
ESR2, estrogen receptor b 0.41 6 0.03 0.42 6 0.03 NS
Adipogenesis, lipogenesis, and lipolysis
ACACA, acetyl CoA carboxylase 0.76 6 0.09 0.65 6 0.11 NS
UCP2, uncoupling protein 2 0.44 6 0.04 0.46 6 0.03 NSa
FASN, fatty acid synthase 0.65 6 0.07 0.62 6 0.07 NS
LIPE, hormone-sensitive lipase 1.28 6 0.17 0.99 6 0.14 NS
PLIN2, perilipin 2 0.70 6 0.07 0.55 6 0.05 NS
LKB1, liver kinase B1 1.44 6 0.19 0.98 6 0.15 0.030a
CTNNB1, b-catenin 0.62 6 0.04 0.45 6 0.02 0.023
PNPLA2, adipose triglyceride lipase 0.58 6 0.07 0.62 6 0.08 NSa
PPARG, peroxisome proliferator-activated
receptor g
0.91 6 0.11 0.68 6 0.10 NSa
PPARGC1A, PGC-1a 0.67 6 0.08 0.58 6 0.08 NS
Lipid and sterol metabolism
CETP, cholesterol ester transfer protein 0.62 6 0.14 0.90 6 0.24 NSa
LPL, lipoprotein lipase 1.25 6 0.07 1.08 6 0.14 NSa
SREBF1, sterol regulatory element binding
transcription factor 1
0.86 6 0.10 0.70 6 0.12 NS
SREBF2, sterol regulatory element binding
transcription factor 2
0.76 6 0.64 6 NSa
Adipokines
IL6, interleukin-6 0.87 6 0.15 1.00 6 0.20 NSa
LEP, leptin 0.92 6 0.10 0.55 6 0.06 0.003a
ADIPOQ, adiponectin 1.28 6 0.10 1.17 6 0.06 NSb
Miscellaneous
IGF1R, IGF-1 receptor 0.73 6 0.06 0.62 6 0.04 NS
IGF1, insulin-like growth factor-1 0.67 6 0.05 0.64 6 0.05 NS
AGT, angiotensinogen 0.86 6 0.08 0.95 6 0.14 NS
ADRA2A, a-2-adrenergic receptor 0.95 6 0.09 0.83 6 0.11 NSa
ARDB1, b-1-adrenergic receptor 0.74 6 0.07 0.65 6 0.05 NSa
Data are presented as mean 6 SEM (relative to cyclophyllin).
Abbreviation: NS, not significant.
aCompared with independent-samples Student t test (data log transformed where not normally distributed as determined by Kolmogorov-Smirnov test).
bIndependent-samples Mann-Whitney U test where transformation did not result in normally distributed data.
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evidence of regulation of expression by sex hormones,
but surprisingly, we did not find many changes. b-Cat-
enin transcript levels, a central component of WNT
signaling regulated by sex steroids (32, 33), were higher
in women treated with aromatase inhibitors. LKB1, an
upstream activator of AMPK upregulated by estradiol
(34) that promotes fatty acid oxidation and suppresses
fatty acid synthesis in adipocytes, had paradoxically
higher transcript levels in women receiving aromatase
inhibitor treatment, although we did not assess LKB1
phosphorylation. The differences in transcript levels were
consistent with an antiadipogenic effect (increased LKB1
and b-catenin), even though fat mass was increased
and leptin mRNA levels were higher with aromatase
inhibition.
In this study, diastolic (but not systolic) blood pressure
was higher in patients receiving aromatase inhibitor
treatment than in control subjects, despite a higher
proportion of antihypertensive therapy in the former.
Polymorphisms in CYP19 have been associated with
differences in diastolic blood pressure in women (35).
The lack of difference in fasting lipid profile with aro-
matase inhibition is broadly in accord with existing
evidence. Prospective evaluation of cholesterol after
anastrozole therapy did not detect any significant
difference in fasting lipid profile (36).
The major limitation of the study is the possibility of
confounding by the history of breast cancer only among
the group taking aromatase inhibitors. We achieved
satisfactory matching with respect to age, weight, waist
circumference, and BMI between groups. The BMI
matching addressed a potentially important limitation
of the case-control design, because increasing BMI is
associated with a higher risk of breast cancer in post-
menopausal women (37). Diabetes (38), metabolic
syndrome (39), and insulin resistance (40) have been
reported as risk factors for breast cancer, although the
relationship with diabetes is attenuated by correction for
BMI (41). Furthermore, our cohort was well matched for
glucose tolerance status and no differences were observed
in fasting insulin resistance as determined by HOMA-IR.
This is consistent with our previous observation that
aromatase inhibition is likely to mediate increased insulin
resistance through reduced peripheral glucose disposal in
skeletal muscle (12) (captured by the dynamic insulin
sensitivity index but not the static HOMA-IR). Although
there is a recognized association between increased
height and postmenopausal breast cancer risk (37), the
mean height of the womenwith breast cancer was shorter
than that of the control group in this study. Attendance at
breast cancer screening (control group) is associated with
affluence (42), which, in turn, is associated with lower
prevalence of obesity and type 2 diabetes (43); however,
we found no evidence of disparity in affluence between
groups. With the exception of breast cancer, patients and
control subjects were generally in good health, as man-
dated by the study exclusion criteria. There was a dis-
parity in levothyroxine-treated participants between
groups. If levothyroxine therapy is associated with al-
terations in body composition or insulin sensitivity,
this could represent a confounder. Reassuringly, post-
menopausal women treated with thyroidectomy and
subsequent levothyroxine did not change in weight or
body composition (44). Thiazide diuretic use has been
associated with altered glucose homeostasis (through
attenuated insulin secretion) (45), although a large
prospective study found no increased diabetes risk with
thiazide diuretics (46). Overall, therefore, we did not
find evidence to support confounding of our primary
observations by selection bias operating between the
two groups.
In conclusion, as hypothesized, aromatase inhibition
was associated with insulin resistance and differences in
body composition, although this manifested as reduced
lean mass rather than, as predicted, a shift from peripheral
to central adiposity. These results have potentially impor-
tant clinical implications and should prompt a more
comprehensive assessment of the metabolic effects of aro-
matase inhibitors in women with breast cancer.
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